Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma.

It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.

It is given by intravenous infusion.

The combination is indicated for the first line treatment of advanced,  unresectable or metastatic, melanoma in people aged twelve years of age and older.

Leave a Reply

Your email address will not be published. Required fields are marked *